| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
|
Gettinger, Scott N
|
|
2016
|
17 |
12 |
p. 1683-1696
|
article
|
| 2 |
A still missing piece of the FIRE-3 puzzle
|
Antoniotti, Carlotta
|
|
2016
|
17 |
12 |
p. e515
|
article
|
| 3 |
A still missing piece of the FIRE-3 puzzle – Authors' reply
|
Stintzing, Sebastian
|
|
2016
|
17 |
12 |
p. e516
|
article
|
| 4 |
A woman living with breast cancer: a true “hell raiser”
|
Morgan, Jules
|
|
2016
|
17 |
12 |
p. 1640
|
article
|
| 5 |
Biomarkers for outcome upon MAPK inhibition in melanoma
|
Blank, Christian
|
|
2016
|
17 |
12 |
p. 1634-1636
|
article
|
| 6 |
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
|
Drilon, Alexander
|
|
2016
|
17 |
12 |
p. 1653-1660
|
article
|
| 7 |
Carcinogenicity of pentachlorophenol and some related compounds
|
Guyton, Kathryn Z
|
|
2016
|
17 |
12 |
p. 1637-1638
|
article
|
| 8 |
Correction to Lancet Oncol 2016; 17: 1482
|
|
|
2016
|
17 |
12 |
p. e519
|
article
|
| 9 |
Drug approval by regulators: who watches the watchers?
|
The Lancet Oncology,
|
|
2016
|
17 |
12 |
p. 1621
|
article
|
| 10 |
Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer
|
Gadgeel, Shirish M
|
|
2016
|
17 |
12 |
p. 1627-1628
|
article
|
| 11 |
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
|
Neal, Joel W
|
|
2016
|
17 |
12 |
p. 1661-1671
|
article
|
| 12 |
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
|
Long, Georgina V
|
|
2016
|
17 |
12 |
p. 1743-1754
|
article
|
| 13 |
Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome
|
Migden, Michael
|
|
2016
|
17 |
12 |
p. 1631-1632
|
article
|
| 14 |
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|
Al-Batran, Salah-Eddin
|
|
2016
|
17 |
12 |
p. 1697-1708
|
article
|
| 15 |
Hyperprogressive disease with anti-PD-1 and anti-PD-L1
|
Brower, Vicki
|
|
2016
|
17 |
12 |
p. e527
|
article
|
| 16 |
Hypofractionated radiotherapy for prostate cancer
|
Motwani, Sabin B
|
|
2016
|
17 |
12 |
p. e517
|
article
|
| 17 |
Hypofractionated radiotherapy for prostate cancer – Authors' reply
|
Dearnaley, David
|
|
2016
|
17 |
12 |
p. e518
|
article
|
| 18 |
Imaginative transformations: breast cancer and art
|
Swain, Kelley
|
|
2016
|
17 |
12 |
p. 1641
|
article
|
| 19 |
Incidence of breast cancer in women with type 2 diabetes
|
Burki, Talha Khan
|
|
2016
|
17 |
12 |
p. e523
|
article
|
| 20 |
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Tang, Jean Y
|
|
2016
|
17 |
12 |
p. 1720-1731
|
article
|
| 21 |
In the Kingdom of the Sick
|
De Ambrogi, Marco
|
|
2016
|
17 |
12 |
p. 1642
|
article
|
| 22 |
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|
Gomez, Daniel R
|
|
2016
|
17 |
12 |
p. 1672-1682
|
article
|
| 23 |
MNX1: a novel prostate cancer oncogene
|
Das, Manjulika
|
|
2016
|
17 |
12 |
p. e521
|
article
|
| 24 |
More than words
|
Berman, Philippa
|
|
2016
|
17 |
12 |
p. 1640
|
article
|
| 25 |
Neurological sequelae of cancer immunotherapies and targeted therapies
|
Wick, Wolfgang
|
|
2016
|
17 |
12 |
p. e529-e541
|
article
|
| 26 |
Oesophageal adenocarcinoma and Barrett's oesophagus
|
Das, Manjulika
|
|
2016
|
17 |
12 |
p. e524
|
article
|
| 27 |
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
|
Goss, Glenwood
|
|
2016
|
17 |
12 |
p. 1643-1652
|
article
|
| 28 |
Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat
|
Zugazagoitia, Jon
|
|
2016
|
17 |
12 |
p. 1622-1623
|
article
|
| 29 |
Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma
|
Badgwell, Brian
|
|
2016
|
17 |
12 |
p. 1628-1629
|
article
|
| 30 |
Phase 1/2 study of blinatumomab in relapsed paediatric ALL
|
Brower, Vicki
|
|
2016
|
17 |
12 |
p. e525
|
article
|
| 31 |
Pomalidomide for symptomatic Kaposi's sarcoma
|
Burki, Talha Khan
|
|
2016
|
17 |
12 |
p. e526
|
article
|
| 32 |
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
|
Gibney, Geoffrey T
|
|
2016
|
17 |
12 |
p. e542-e551
|
article
|
| 33 |
President Trump: into the unknown…
|
The Lancet Oncology,
|
|
2016
|
17 |
12 |
p. 1621
|
article
|
| 34 |
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
|
Franko, Jan
|
|
2016
|
17 |
12 |
p. 1709-1719
|
article
|
| 35 |
PR1 peptide vaccine in myeloid malignancies
|
Gilbert, Judith A
|
|
2016
|
17 |
12 |
p. e520
|
article
|
| 36 |
Radical treatment of synchronous oligometastases from NSCLC
|
De Ruysscher, Dirk
|
|
2016
|
17 |
12 |
p. 1625-1626
|
article
|
| 37 |
Referral criteria for outpatient specialty palliative cancer care: an international consensus
|
Hui, David
|
|
2016
|
17 |
12 |
p. e552-e559
|
article
|
| 38 |
Regorafenib: efficacy in multiple refractory sarcoma types
|
Healey, John H
|
|
2016
|
17 |
12 |
p. 1633-1634
|
article
|
| 39 |
Relevance of randomised controlled trials in oncology
|
Tannock, Ian F
|
|
2016
|
17 |
12 |
p. e560-e567
|
article
|
| 40 |
RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
|
Rosell, Rafael
|
|
2016
|
17 |
12 |
p. 1623-1625
|
article
|
| 41 |
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Mir, Olivier
|
|
2016
|
17 |
12 |
p. 1732-1742
|
article
|
| 42 |
Suicide in survivors of childhood and young adult cancers
|
Brower, Vicki
|
|
2016
|
17 |
12 |
p. e522
|
article
|
| 43 |
Trastuzumab emtansine for HER2-positive breast cancer
|
Venkatesan, Priya
|
|
2016
|
17 |
12 |
p. e528
|
article
|
| 44 |
Treatment of colorectal peritoneal metastases requires multidisciplinary efforts
|
Goéré, Diane
|
|
2016
|
17 |
12 |
p. 1630-1631
|
article
|
| 45 |
Turmeric: a spice for life?
|
Balachandran, Kirsty
|
|
2016
|
17 |
12 |
p. 1639
|
article
|
| 46 |
Vinorelbine-induced chemotherapy port extravasation
|
Das, Chandan Krushna
|
|
2016
|
17 |
12 |
p. e568
|
article
|
Journal description